Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
She has held senior positions at Coca-Cola in China and PepsiCo in India
Net Profit increased by 15% to Rs. 146 crores in Q4 FY25 and 19% to Rs. 660 crores in FY25
Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India
The CDMO upgrade represents a transformational step for Remedium Lifecare
The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025
Subscribe To Our Newsletter & Stay Updated